Abbott is poised to see robust growth in diabetes care with FDA approval of FreeStyle Libre.
Abbott’s third-quarter results slightly outpaced our expectations on the top line, but slight adjustments to our assumptions were not material enough to shift our fair value estimate. Abbott has begun to reap the rewards of waxing product cycles this year, and we expect this to continue through 2018 thanks to increasing adoption of new products, as well as others on deck for approval. The development and regulatory delays that dogged St. Jude Medical in 2015 and 2016 have been ironed out, and Ab...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.